The GS Xceed system was shown to reduce cell line development timelines by up to six weeks over the existing CHOK1SV based system and has achieved titers of up to 6g/l.
Lonza Development Services head Janet White said, "Our new GS Xceed Gene Expression System allows our customers to significantly reduce their timelines for the generation of clinical supply material while continuing to achieve titers well above industry standards."
According to the company, both emerging and established companies can access the new system by either a research evaluation agreement or a commercial license.
The CHOK1SV GS Knock-out host cell line, a derivative of Lonza’s suspension adapted CHOK1SV host cell line in which both alleles of the endogenous glutamine synthetase gene have been knocked out, is the key element of the new system.
Cell lines are selected in Lonza’s Version 8 Commercial Platform Process thereby allowing faster future scale-up into a GMP manufacturing system.
The complete GS Xceed System includes, cGMP banked CHOK1SV GS-KO host cells, GS expression vectors, full protocols, access to the comapny’s Commercial Platform Production Process and access to GS technical team.